Clinical biomarkers in drug discovery and development

By Richard Frank, Richard Hargreaves. Nature reviews. Drug discovery, 2003

762 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Multiplexed protein measurement: technologies and applications of protein and antibody arrays (2006, background): “Protein arrays for biomarker development A biomarker is a measurable 'biological marker' that correlates with a specific outcome or state: this subject has been reviewed recently in this journa”
Imaging and cancer: A review (2008, methodology): “In vitro, cellular, preclinical and clinical imaging are used in the various phases of drug discovery (Figure 3) and integrated in data management systems using IT (Hehenberger et al., 2007; Czernin et al., 2006; Frank and Hargreaves, 2003; Tatum and Hoffman, 2000).”
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010, neutral): “To qualify for these purposes, a biomarker must be measured by reliable and validated methods, must be sensitive and specific when used as diagnostic markers, must be sensitive to the effects of a drug, and must be predictive of clinical outcome”
Structural connectomics in brain diseases (2013, positive): “Although there is still room for progress, MS is probably one of the chronic neurodegenerative disease were MRI as a neuroimaging biomarker has had the greatest impact on disease management (Frank and Hargreaves, 2003).”